A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Public ClinicalTrials.gov record NCT02669758. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.
Study identification
- NCT ID
- NCT02669758
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 281 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 19, 2016
- Primary completion
- Jun 28, 2018
- Completion
- Jun 28, 2018
- Last update posted
- Jul 25, 2019
2016 – 2018
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Investigational Site | Little Rock | Arkansas | 72211 | — |
| Alkermes Investigational Site | Springdale | Arkansas | 72764 | — |
| Alkermes Investigational Site | Culver City | California | 90230 | — |
| Alkermes Investigational Site | Garden Grove | California | 92845 | — |
| Alkermes Investigational Site | Lemon Grove | California | 91945 | — |
| Alkermes Investigational Site | Orange | California | 92868 | — |
| Alkermes Investigational Site | San Diego | California | 92103 | — |
| Alkermes Investigational Site | Miami | Florida | 33161 | — |
| Alkermes Investigational Site | Chicago | Illinois | 60640 | — |
| Alkermes Investigational Site | St Louis | Missouri | 63141 | — |
| Alkermes Investigational Site | Las Vegas | Nevada | 89102 | — |
| Alkermes Investigational Site | Marlton | New Jersey | 08053 | — |
| Alkermes Investigational Site | Dayton | Ohio | 45417 | — |
| Alkermes Investigational Site | Dallas | Texas | 75243 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02669758, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 25, 2019 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02669758 live on ClinicalTrials.gov.